Voyager Therapeutics, Inc.
About Voyager Therapeutics, Inc.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $40.4M
- Net income
- -$119.7M
- Total assets
- $252.3M
- Market cap
- $201.2M
- Operating margin
- -326.6%
- Net margin
- -296.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $40.4M
- Operating expenses
- $172.2M
- Operating income
- -$131.8M
- Income tax
- $144.0K
- Net income
- -$119.7M
- EPS (basic)
- $-2.04
- EPS (diluted)
- $-2.04
Balance sheet
- Total assets
- $252.3M
- Current assets
- $202.7M
- Total liabilities
- $56.2M
- Current liabilities
- $26.5M
- Shareholders’ equity
- $196.1M
Cash flow
- Operating cash flow
- -$132.5M
- Investing cash flow
- $125.4M
- Financing cash flow
- $816.0K
- Net cash flow
- -$6.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $201.2M
- EPS (diluted)
- $-2.04
- Shares outstanding
- 59.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 11, 2015
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $119.7M in FY2025.
- Revenue grew 8% from FY2021 to FY2025.
- Trading 37% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Voyager Therapeutics, Inc..
Write a review
News about Voyager Therapeutics, Inc.
News & sentiment via Polygon.io
